COGT · Cogent Biosciences, Inc.
$30.93
-0.09 (-0.29%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$5.62B
Shares
173.52M
Volume · Oct 5
1.79M
Avg daily vol (3M)
1.96M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.02
Open$32.12
Day$30.86–32.29
52W close$14.13–42.84
Avg vol 30d1.9M
Short int18.1M · 10.4% float · 11.8d
Short vol35%
Last earningsMay 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.87M
Trailing 12 months
Net income (TTM)
−$377.18M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-1,044.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+49.4%
Year over year · more shares
Price change (1Y)
+110.3%
Trailing year
Short interest
10.4%
Latest settlement · 11.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−14%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−15%
trailing
YTD return
−13%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $36 › 200d $36 — 200d above 50d
Institutional flow
Flat
1 of 327 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.45% of float · ▼ -3.3% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
327 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−65%
Y/Y
EPS growth
−11%
Y/Y
Free cash flow
$-266.0M
Balance sheet
$89.1M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Death cross
50d $36 › 200d $36 — 200d above 50d
Institutional flow
Flat
1 of 327 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.45% of float · ▼ -3.3% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
327 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $31 · 59%
Range high $43
vs 200-day avg -15%
vs 50-day avg -14%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COGT
this stock
Cogent Biosciences, Inc.
|
$5.62B | -12.7% | -65.0% | — | 10.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COGT | -4.0% | -11.2% | -15.1% | -3.1% | -12.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -3.8% | -10.8% | -27.2% | -4.0% | -25.5% |